Kiora Pharmaceuticals Stock Analysis
| KPRX Stock | USD 0.49 0.02 3.92% |
Kiora Pharmaceuticals is undervalued with Real Value of 3.45 and Target Price of 12.33. The main objective of Kiora Pharmaceuticals stock analysis is to determine its intrinsic value, which is an estimate of what Kiora Pharmaceuticals is worth, separate from its market price. There are two main types of Kiora Pharmaceuticals' stock analysis: fundamental analysis and technical analysis. Fundamental analysis focuses on the financial and economic factors that affect Kiora Pharmaceuticals' performance, such as revenue growth, earnings, and financial stability. Technical analysis, on the other hand, focuses on the price and volume data of Kiora Pharmaceuticals' stock to identify patterns and trends that may indicate its future price movements.
The Kiora Pharmaceuticals stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Kiora Pharmaceuticals is usually not traded on Thanksgiving Day, Christmas Day, New Year 's Day, Dr . Martin Luther King Jr 's Birthday, Washington 's Birthday, Good Friday, Memorial Day, Juneteenth Holiday, Independence Day, Labour Day. Kiora Stock trading window is adjusted to America/New York timezone. Here, you can get updates on important government artifacts, including earning estimates, SEC corporate filings, announcements, and Kiora Pharmaceuticals' ongoing operational relationships across important fundamental and technical indicators.
Kiora |
Kiora Stock Analysis Notes
About 18.0% of the company shares are owned by institutional investors. The book value of Kiora Pharmaceuticals was now reported as 0.79. The company recorded a loss per share of 2.69. Kiora Pharmaceuticals last dividend was issued on the 30th of August 2019. The entity had 1:40 split on the 27th of September 2022. Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, develops and commercializes therapies for the treatment of ophthalmic diseases in the United States. Kiora Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Salt Lake City, Utah. Kiora Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 14 people. To find out more about Kiora Pharmaceuticals contact Brian Strem at 858 224 9600 or learn more at https://www.kiorapharma.com.Kiora Pharmaceuticals Investment Alerts
Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Kiora Pharmaceuticals' investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Kiora Pharmaceuticals or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
| Kiora Pharmaceuticals had very high historical volatility over the last 90 days | |
| Kiora Pharmaceuticals has some characteristics of a very speculative penny stock | |
| Net Loss for the year was (12.51 M) with loss before overhead, payroll, taxes, and interest of (5.14 M). | |
| Kiora Pharmaceuticals currently holds about 2.43 M in cash with (9.56 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.64, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Kiora Pharmaceuticals has a frail financial position based on the latest SEC disclosures | |
| Latest headline from news.google.com: Kiora Pharmaceuticals Trading Down 7.9 percent - Defense World |
Kiora Pharmaceuticals Upcoming and Recent Events
Earnings reports are used by Kiora Pharmaceuticals to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Kiora Pharmaceuticals previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 28th of March 2024 Upcoming Quarterly Report | View | |
| 14th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 28th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Kiora Largest EPS Surprises
Earnings surprises can significantly impact Kiora Pharmaceuticals' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2024-03-25 | 2023-12-31 | -0.42 | -0.47 | -0.05 | 11 | ||
2023-08-08 | 2023-06-30 | -1.07 | -0.79 | 0.28 | 26 | ||
2022-03-02 | 2021-12-31 | -0.3 | -0.66 | -0.36 | 120 |
Kiora Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Kiora Pharmaceuticals is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Kiora Pharmaceuticals backward and forwards among themselves. Kiora Pharmaceuticals' institutional investor refers to the entity that pools money to purchase Kiora Pharmaceuticals' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Advisor Group Holdings, Inc. | 2023-12-31 | 36.0 | Morgan Stanley - Brokerage Accounts | 2023-12-31 | 8.0 | Albion Financial Group (utah) | 2023-12-31 | 6.0 | Sabby Management Llc | 2023-09-30 | 0.0 | Fmr Inc | 2023-12-31 | 0.0 | Xtx Topco Ltd | 2023-12-31 | 0.0 | Two Sigma Securities, Llc | 2023-09-30 | 0.0 | Walleye Trading Advisors, Llc | 2023-09-30 | 0.0 | Hrt Financial Llc | 2023-09-30 | 0.0 | Captrust Financial Advisors | 2023-12-31 | 80 K | Geode Capital Management, Llc | 2023-12-31 | 37.2 K |
Kiora Market Capitalization
The company currently falls under 'Micro-Cap' category with a current market capitalization of 13.39 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Kiora Pharmaceuticals's market, we take the total number of its shares issued and multiply it by Kiora Pharmaceuticals's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.Kiora Profitablity
Kiora Pharmaceuticals' profitability indicators refer to fundamental financial ratios that showcase Kiora Pharmaceuticals' ability to generate income relative to its revenue or operating costs. If, let's say, Kiora Pharmaceuticals is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Kiora Pharmaceuticals' executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Kiora Pharmaceuticals' profitability requires more research than a typical breakdown of Kiora Pharmaceuticals' financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (2.55) | (2.68) | |
| Return On Capital Employed | (0.72) | (0.68) | |
| Return On Assets | (0.91) | (0.96) | |
| Return On Equity | (2.05) | (1.95) |
Management Efficiency
Kiora Pharmaceuticals has return on total asset (ROA) of (0.3354) % which means that it has lost $0.3354 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.4288) %, meaning that it created substantial loss on money invested by shareholders. Kiora Pharmaceuticals' management efficiency ratios could be used to measure how well Kiora Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -2.68 in 2024. Return On Capital Employed is likely to rise to -0.68 in 2024. At this time, Kiora Pharmaceuticals' Other Current Assets are fairly stable compared to the past year. Total Current Assets is likely to rise to about 5.6 M in 2024, whereas Total Assets are likely to drop slightly above 11.7 M in 2024.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 1.26 | 1.32 | |
| Net Current Asset Value | 0.00 | 0.00 | |
| Tangible Asset Value | 0.00 | 0.00 | |
| Tangible Book Value Per Share | (0.56) | (0.59) | |
| Enterprise Value Over EBITDA | (0.02) | (0.02) | |
| Price Book Value Ratio | 0.41 | 0.43 | |
| Enterprise Value Multiple | (0.02) | (0.02) | |
| Price Fair Value | 0.41 | 0.43 | |
| Enterprise Value | 181.7 K | 172.6 K |
The analysis of Kiora Pharmaceuticals' management efficiency is an essential part of evaluating and assessing the financial and operational performance of the entity. It is also vital to analyze Kiora Pharmaceuticals' future growth prospects and the overall market conditions to determine the value and potential of its stock. The analysis involves studying a range of financial metrics such as revenue, earnings, profit margins, cash flow, debt, market share, and external factors such as economic trends, industry outlook, competition, and government regulations. The goal of Kiora Stock analysis is to determine whether it is undervalued, fairly valued, or overvalued and to make informed investment decisions.
Beta (0.26) |
Technical Drivers
As of the 19th of April, Kiora Pharmaceuticals secures the Mean Deviation of 4.68, downside deviation of 6.12, and Risk Adjusted Performance of 0.028. Kiora Pharmaceuticals technical analysis lets you operate historical price patterns with an objective to determine a pattern that forecasts the direction of the firm's future prices. Strictly speaking, you can use this information to find out if the firm will indeed mirror its model of past prices, or the prices will eventually revert. We were able to interpolate data for nineteen technical drivers for Kiora Pharmaceuticals, which can be compared to its peers in the industry. Please verify Kiora Pharmaceuticals standard deviation, value at risk, as well as the relationship between the Value At Risk and kurtosis to decide if Kiora Pharmaceuticals is priced some-what accurately, providing market reflects its recent price of 0.49 per share. As Kiora Pharmaceuticals is a penny stock we also strongly advise to check its total risk alpha numbers.Kiora Pharmaceuticals Price Movement Analysis
Incorrect Input. Please change your parameters or increase the time horizon required for running this function. The output start index for this execution was zero with a total number of output elements of zero. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Kiora Pharmaceuticals middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Kiora Pharmaceuticals. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.
Kiora Pharmaceuticals Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Kiora Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Kiora Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Kiora Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Shapiro Aron over six months ago Acquisition by Shapiro Aron of 5000 shares of Kiora Pharmaceuticals subject to Rule 16b-3 | ||
Wirostko Barbara over six months ago Acquisition by Wirostko Barbara of 9600 shares of Kiora Pharmaceuticals subject to Rule 16b-3 | ||
Shapiro Aron over a year ago Acquisition by Shapiro Aron of 8000 shares of Kiora Pharmaceuticals subject to Rule 16b-3 |
Kiora Pharmaceuticals Predictive Daily Indicators
Kiora Pharmaceuticals intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Kiora Pharmaceuticals stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
| Accumulation Distribution | 3743.4 | |||
| Daily Balance Of Power | (0.50) | |||
| Rate Of Daily Change | 0.96 | |||
| Day Median Price | 0.51 | |||
| Day Typical Price | 0.5 | |||
| Price Action Indicator | (0.03) | |||
| Period Momentum Indicator | (0.02) |
Kiora Pharmaceuticals Forecast Models
Kiora Pharmaceuticals' time-series forecasting models are one of many Kiora Pharmaceuticals' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Kiora Pharmaceuticals' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.About Kiora Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how Kiora Pharmaceuticals prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Kiora shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Kiora Pharmaceuticals. By using and applying Kiora Stock analysis, traders can create a robust methodology for identifying Kiora entry and exit points for their positions.
| Last Reported | Projected for Next Year | ||
| Pretax Profit Margin | (770.53) | (732.01) | |
| Operating Profit Margin | (780.98) | (741.93) | |
| Net Loss | (771.68) | (733.10) | |
| Gross Profit Margin | (17.94) | (17.05) |
Current Kiora Analysis - Recommendations
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Kiora analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Kiora analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
| Target Price | Advice | # of Analysts | |
| 12.33 | Strong Buy | 3 | Odds |
Most Kiora analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Kiora stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Kiora Pharmaceuticals, talking to its executives and customers, or listening to Kiora conference calls.
Kiora Stock Analysis Indicators
Kiora Pharmaceuticals stock analysis indicators help investors evaluate how Kiora Pharmaceuticals stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Kiora Pharmaceuticals shares will generate the highest return on investment. By understating and applying Kiora Pharmaceuticals stock analysis, traders can identify Kiora Pharmaceuticals position entry and exit signals to maximize returns.
| Begin Period Cash Flow | 6 M | |
| Common Stock Shares Outstanding | 4.8 M | |
| Total Stockholder Equity | 6.1 M | |
| Tax Provision | 90.3 K | |
| Property Plant And Equipment Net | 115 K | |
| Cash And Short Term Investments | 2.5 M | |
| Cash | 2.5 M | |
| Accounts Payable | 206.3 K | |
| Net Debt | -2.3 M | |
| 50 Day M A | 0.6238 | |
| Total Current Liabilities | 1.6 M | |
| Other Operating Expenses | 8.7 M | |
| Non Current Assets Total | 9 M | |
| Forward Price Earnings | 2.129 | |
| Non Currrent Assets Other | 40.8 K | |
| Stock Based Compensation | 754.9 K |
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Kiora Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area. For more information on how to buy Kiora Stock please use our How to Invest in Kiora Pharmaceuticals guide.You can also try the USA ETFs module to find actively traded Exchange Traded Funds (ETF) in USA.
Complementary Tools for Kiora Stock analysis
When running Kiora Pharmaceuticals' price analysis, check to measure Kiora Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kiora Pharmaceuticals is operating at the current time. Most of Kiora Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Kiora Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Kiora Pharmaceuticals' price. Additionally, you may evaluate how the addition of Kiora Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk |
Is Kiora Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Kiora Pharmaceuticals. If investors know Kiora will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Kiora Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.69) | Revenue Per Share 0.002 | Return On Assets (0.34) | Return On Equity (1.43) |
The market value of Kiora Pharmaceuticals is measured differently than its book value, which is the value of Kiora that is recorded on the company's balance sheet. Investors also form their own opinion of Kiora Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Kiora Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Kiora Pharmaceuticals' market value can be influenced by many factors that don't directly affect Kiora Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Kiora Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Kiora Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Kiora Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.